stockrow
Monday 9 November 2026
Export CGEN’s income statement to Excel — free account
Compugen Ltd.
CGENCompugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024.
- Revenue
- +107.0%
- EPS
- +12.5%
- Free cash flow
- −155.4%
Quarter to June 2026, against a year earlier
1.96
0.04
+2.08%
Follow CGEN
Alert me
Compugen Ltd. (CGEN) P/E ratio
As of 6 November 2026, Compugen Ltd. (CGEN) trades at a P/E ratio of 5.2×. Over the past ten years it has ranged from 0.0× (December 2025) to 79.4× (October 2024); the current reading is higher than 92% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 4.1× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 5.6× | (2.17%) |
| Mar 2026 | 5.8× | 39.22% |
| Dec 2025 | 4.1× | — |
| Sep 2025 | 0.0× | — |
| 20 more quarters | Free account |
Against its own ten years
Low 0.0×
High 79.4×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRDA Entrada Therapeutics, Inc. compare | n/m |
| RNA Atrium Therapeutics, Inc. compare | n/m |
| KROS Keros Therapeutics, Inc. compare | n/m |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | n/m |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| UPB Upstream Bio, Inc. compare | n/m |
| ACOG Alpha Cognition Inc. compare | n/m |
| PRQR ProQR Therapeutics N.V. compare | n/m |
| CGEN Compugen Ltd. | 5.2× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)